The company has not filed an annual or quarterly report since its Q2 FY2022 10-Q, filed Aug 8, 2022. Its latest SEC filing is a SC 13G/A from Feb 14, 2023.
10-Q for Q2 FY2022, filed Aug 8, 2022
The sections below describe the company as of the FY2021 annual report.
Sells Oxbryta and develops other medicines for people with sickle cell disease.
10-K for FY2021, filed Feb 23, 2022We are a biopharmaceutical company driven by our mission to discover, develop and deliver life-changing treatments that provide hope to…View ↗
We continue to make progress on our mission to bring innovative therapies to the SCD community. Our first medicine, Oxbryta, an oral…View ↗
Beyond Oxbryta, we are engaged in other research and development activities. Our development program includes inclacumab, a P-selectin…View ↗
Sells Oxbryta to specialty pharmacies and a specialty distributor, with payment terms typically 30-60 days after delivery.
10-K for FY2021, filed Feb 23, 2022
$194.7M
10-K for FY2021, filed Feb 23, 2022
$194.7M ↗
U.S. sales go to specialty pharmacies and a specialty distributor, which dispense Oxbryta to patients or resell it to hospitals and certain pharmacies. Outside the U.S., the company uses a distribution partner in the Middle East and was building sales teams in Europe.
10-K for FY2021, filed Feb 23, 2022Our product sales consist of U.S. sales of Oxbryta, which we began shipping to customers in December 2019. Prior to December 2019, we had…View ↗
With respect to commercializing Oxbryta outside of the United States, we have established in Europe strategically located subsidiaries and…View ↗
In September 2020, we entered into an exclusive agreement with Biopharma-MEA to distribute Oxbryta in the GCC region. Biopharm-MEA is…View ↗
No. It lost $303.1M in FY2021.
10-K for FY2021, filed Feb 23, 2022
−$287.7MView ↗
10-K for FY2021, filed Feb 23, 2022
−$303.1MView ↗
10-K for FY2021, filed Feb 23, 2022
−$260MView ↗
10-Q for Q2 FY2022, filed Aug 8, 2022
−$82.5MView ↗
8-K, filed Oct 5, 2022
On the Closing Date, pursuant to and in accordance with the Merger Agreement, Merger Sub merged with and into GBT, with GBT surviving the…View ↗
8-K, filed Aug 8, 2022
At the effective time of the Merger (the “Effective Time”), each of the Company’s issued and outstanding shares of common stock, par value…View ↗
From clinical candidate to marketed medicine
The older report described voxelotor as a product candidate in clinical trials; the latest report describes Oxbryta as an approved medicine sold in the United States.
10-K for FY2018, filed Feb 27, 2019 10-K for FY2021, filed Feb 23, 2022
Competes with Medunik USA, Bristol-Myers Squibb, Emmaus Medical, Novartis Pharmaceuticals, Forma Therapeutics, Agios Pharmaceuticals, Fulcrum Therapeutics, and bluebird bio
10-K for FY2021, filed Feb 23, 2022With respect to Oxbryta, inclacumab and GBT601, we face competition from the three currently FDA-approved treatments: hydroxyurea (marketed…View ↗
Loading...
